Advertisement

Lung

, Volume 196, Issue 1, pp 115–124 | Cite as

Concerns About Lung Cancer Among Prisoners

  • Luc Renault
  • Emmanuel Perrot
  • Eric Pradat
  • Christophe Bartoli
  • Laurent Greillier
  • Anne Remacle-Bonnet
  • Norbert Telmon
  • Julien Mazières
  • Laurent Molinier
  • Sébastien Couraud
LUNG CANCER

Abstract

Background

Few studies have looked at lung cancer in prisoners, despite this population is possibly at increased risk of malignancy. In a previous study, we found an early onset of lung cancer in prisoners. Thus, the present CARCAN study was aimed at assessing the epidemiological characteristics, management, prognosis, and incidence of lung cancer in prisoners compared to a sample of non-prisoner patients.

Method

We performed a multi-center observational case–control study. Cases were prisoners diagnosed with lung cancer from 2005 to 2013. Controls were non-prisoner lung cancer patients selected from hospital databases and randomly matched to cases (targeted case–control ratio: 1:3). Incidence rates in both groups were calculated using national statistics.

Results

Seventy-two cases and 170 controls met inclusion criteria. Cases were mainly men (99%). Mean age at diagnosis was 52.9 (± 11.0) in cases and 64.3 (± 10.1) in controls (p < 0.0001). More case patients were current smokers compared to control patients (83% vs 53%; p < 0.0001). We found no significant differences between the two groups as concerns histologic types, TNM stages at diagnosis, initially-employed treatments, times to management or survival. Incidence rates (2008–2012) in male prisoners were higher than those in the general population in all concerned age groups.

Conclusion

There is a shift of lung cancer toward young people in prisons. However, the presentation, management, and prognosis of lung cancer are similar between prisoners and non-prisoners. These finding could justify a specific screening policy for the incarcerated populations.

Keywords

Lung cancer Prison Tobacco smoking Incidence rate Epidemiology 

Notes

Acknowledgements

Authors thank M. Kevin Erwin for expert English rewording.

Funding

This study was supported by Grants from AGIRADOM and Chugai Pharma France. The sponsors had no role in the study.

Compliance with Ethical Standards

Conflict of interest

Dr. MOLINIER reports grants, personal fees and non-financial support from SANOFI, personal fees and non-financial support from JANSSEN CILAG, personal fees from ABBVIE, personal fees from NESTLE, outside the submitted work. Dr. COURAUD reports grants from Chugai Pharma France, grants from AGIRADOM, during the conduct of the study; grants and non-financial support from BMS, grants, personal fees and non-financial support from Astra Zeneca, grants, personal fees and non-financial support from Pfizer, grants, personal fees, non-financial support and other from Roche, grants, personal fees, non-financial support and other from Chugai, personal fees and other from MSD, grants, personal fees, non-financial support and other from Boehringer Ingelheim, grants and non-financial support from Sysmex Innostics, grants, personal fees and non-financial support from Lilly, grants from Novartis, grants from Merck, grants and personal fees from Laidet Medical, grants and non-financial support from Amgen, outside the submitted work. Dr. GREILLIER reports grants, personal fees and non-financial support from ROCHE, personal fees and non-financial support from LILLY, grants and personal fees from NOVARTIS, personal fees and non-financial support from PFIZER, personal fees and non-financial support from BRISTOL-MYERS SQUIBB, personal fees and non-financial support from BOEHRINGER INGELHEIM, personal fees and non-financial support from ASTRA-ZENECA, outside the submitted work. Dr. RENAULT reports grants from Chugai Pharma France, grants from AGIRADOM, during the conduct of the study; non-financial support from Grünenthal, outside the submitted work. Other authors have nothing to disclose.

Supplementary material

408_2017_66_MOESM1_ESM.docx (157 kb)
Supplementary material 1 (DOCX 157 kb)
408_2017_66_MOESM2_ESM.docx (24 kb)
Supplementary material 2 (DOCX 23 kb)
408_2017_66_MOESM3_ESM.docx (24 kb)
Supplementary material 3 (DOCX 23 kb)
408_2017_66_MOESM4_ESM.docx (23 kb)
Supplementary material 4 (DOCX 23 kb)
408_2017_66_MOESM5_ESM.docx (25 kb)
Supplementary material 5 (DOCX 25 kb)
408_2017_66_MOESM6_ESM.docx (25 kb)
Supplementary material 6 (DOCX 25 kb)
408_2017_66_MOESM7_ESM.docx (13 kb)
Supplementary material 7 (DOCX 13 kb)
408_2017_66_MOESM8_ESM.docx (18 kb)
Supplementary material 8 (DOCX 18 kb)

References

  1. 1.
    Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R (2000) Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 321:323–329CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Couraud S, Zalcman G, Milleron B, Morin F, Souquet P-J (2012) Lung cancer in never smokers – a review. Eur J Cancer 48:1299–1311.  https://doi.org/10.1016/j.ejca.2012.03.007 CrossRefPubMedGoogle Scholar
  3. 3.
    Brenner DR, McLaughlin JR, Hung RJ (2011) Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS ONE 6:e17479.  https://doi.org/10.1371/journal.pone.0017479 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Berthiller J, Straif K, Boniol M, Voirin N, Benhaïm-Luzon V, Ayoub WB et al (2008) Cannabis smoking and risk of lung cancer in men: a pooled analysis of three studies in Maghreb. J Thorac Oncol 3:1398–1403.  https://doi.org/10.1097/JTO.0b013e31818ddcde CrossRefPubMedGoogle Scholar
  5. 5.
    Sidorchuk A, Agardh EE, Aremu O, Hallqvist J, Allebeck P, Moradi T (2009) Socioeconomic differences in lung cancer incidence: a systematic review and meta-analysis. Cancer Causes Control 20:459.  https://doi.org/10.1007/s10552-009-9300-8 CrossRefPubMedGoogle Scholar
  6. 6.
    Tardon A, Lee WJ, Delgado-Rodriguez M, Dosemeci M, Albanes D, Hoover R et al (2005) Leisure-time physical activity and lung cancer: a meta-analysis. Cancer Causes Control 16:389–397.  https://doi.org/10.1007/s10552-004-5026-9 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ministère de la Justice, France. Les chiffres clés de l’administration pénitentiaire au 1er janvier 2013. http://www.justice.gouv.fr/prison-et-reinsertion-10036/les-chiffres-clefs-10041/ladministration-penitentiaire-en-chiffres-25722.html
  8. 8.
    Carbonnaux M, Fossard G, Amzallag E, Piegay C, Perot E, Chossegros P et al (2013) Earlier onset and poor prognosis of lung cancer in imprisoned patients. Oncology 85:370–377.  https://doi.org/10.1159/000356877 CrossRefPubMedGoogle Scholar
  9. 9.
    Locher C, Debieuvre D, Coëtmeur D, Goupil F, Molinier O, Collon T et al (2013) Major changes in lung cancer over the last ten years in France: the KBP-CPHG studies. Lung Cancer 81:32–38.  https://doi.org/10.1016/j.lungcan.2013.03.001 CrossRefPubMedGoogle Scholar
  10. 10.
    Urbaniak GC, Plous S (2013) Research randomizer (version 4.0). https://www.randomizer.org
  11. 11.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMedGoogle Scholar
  12. 12.
    de Decker L (2009) L’indice de co-morbidité de Charlson. Ann Gérontol 2:159–160.  https://doi.org/10.1684/age.2009.0059 Google Scholar
  13. 13.
    Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE et al (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39–51.  https://doi.org/10.1016/j.jtho.2015.09.009 CrossRefPubMedGoogle Scholar
  14. 14.
    Bouyer J, Hémon D, Cordier S, Derriennic F, Stücker I, Stengel B et al (2009) Epidémiologie: principes et méthodes quantitatives. INSERM, Paris. ISBN 978-2-7430-1167-3Google Scholar
  15. 15.
  16. 16.
    Binder-Foucard F, Belot A, Delafosse P, Remontet L, Woronoff A-S, Bossard N (2013) Estimation de l’incidence et de la mortalité par cancer en France métropolitaine entre 1980 et 2012. Partie 1 - Tumeurs solides. Institut de Veille Sanitaire, France. http://invs.santepubliquefrance.fr/Dossiers-thematiques/Maladies-chroniques-et-traumatismes/Cancers/Surveillance-epidemiologique-des-cancers/Estimations-de-l-incidence-de-la-mortalite-et-de-la-survie/Estimation-de-l-incidence-et-de-la-mortalite-par-cancer-en-France-metropolitaine-entre-1980-et-2012-Tumeurs-solides
  17. 17.
    Institut National de la Statistique et des Etudes Economiques, France. Pyramides des âges - Bilan démographique. https://www.insee.fr/fr/statistiques/1913143?sommaire=1912926
  18. 18.
    Baillargeon J, Black SA, Pulvino J, Dunn K (2000) The disease profile of Texas prison inmates. Ann Epidemiol 10:74–80CrossRefPubMedGoogle Scholar
  19. 19.
    Rosen DL, Wohl DA, Schoenbach VJ (2011) All-cause and cause-specific mortality among black and white North Carolina State Prisoners, 1995–2005. Ann Epidemiol 21:719–726.  https://doi.org/10.1016/j.annepidem.2011.04.007 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Mathew P, Elting L, Cooksley C, Owen S, Lin J (2005) Cancer in an incarcerated population. Cancer 104:2197–2204.  https://doi.org/10.1002/cncr.21468 CrossRefPubMedGoogle Scholar
  21. 21.
    Davies EA, Sehgal A, Linklater KM, Heaps K, Moren C, Walford C et al (2010) Cancer in the London prison population, 1986-2005. J Public Health Oxf Engl 32:526–531.  https://doi.org/10.1093/pubmed/fdq009 CrossRefGoogle Scholar
  22. 22.
    Binswanger IA, Carson EA, Krueger PM, Mueller SR, Steiner JF, Sabol WJ (2014) Prison tobacco control policies and deaths from smoking in United States prisons: population based retrospective analysis. BMJ 349:g4542CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Institut National de la Statistique et des Etudes Economiques, France. Population par âge - Tableaux de l’Économie Française - Édition 2013. https://www.insee.fr/fr/statistiques/1374112?sommaire=1374192
  24. 24.
    Institut national de prévention et d’éducation pour la santé (France), Beck F, Guilbert P, Gautier A (2007) Baromètre santé 2005: attitudes et comportements de santé. Éd. INPES, Saint-DenisGoogle Scholar
  25. 25.
    Mouquet M-C (2005) La santé des personnes entrées en prison en 2003. Etudes et Résultats. http://drees.social-sante.gouv.fr/IMG/pdf/er386.pdf
  26. 26.
    Cochet A, Isnard H (2007) Tuberculose dans les maisons d’arrêt en Île-de-France. Enquête prospective, 1er juillet 2005–30 juin 2006. Rapport dela Cire Ile-de-France et Institut de Veille Sanitaire. http://opac.invs.sante.fr/doc_num.php?explnum_id=3587
  27. 27.
    Institut de Veille Sanitaire, France. Données épidémiologiques/Tuberculose/Maladies à déclaration obligatoire/Maladies infectieuses/Dossiers thématiques/Accueil. http://invs.santepubliquefrance.fr/Dossiers-thematiques/Maladies-infectieuses/Maladies-a-declaration-obligatoire/Tuberculose/Donnees-epidemiologiques
  28. 28.
    Bryere J, Dejardin O, Launay L, Colonna M, Grosclaude P, Launoy G et al (2016) Socioeconomic status and site-specific cancer incidence, a Bayesian approach in a French Cancer Registries Network study. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP.  https://doi.org/10.1097/CEJ.0000000000000326 Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Luc Renault
    • 1
  • Emmanuel Perrot
    • 2
  • Eric Pradat
    • 3
  • Christophe Bartoli
    • 4
    • 5
  • Laurent Greillier
    • 6
    • 7
  • Anne Remacle-Bonnet
    • 8
  • Norbert Telmon
    • 9
    • 10
  • Julien Mazières
    • 11
    • 12
  • Laurent Molinier
    • 13
    • 14
  • Sébastien Couraud
    • 15
    • 16
  1. 1.Faculté de Médecine Lyon EstUniversité Lyon 1LyonFrance
  2. 2.Unité Hospitalière Sécurisée InterrégionaleCentre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de LyonPierre BéniteFrance
  3. 3.Département d’Information MédicaleCentre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de LyonPierre BéniteFrance
  4. 4.UMR 7268 ADES, CNRS, EFSAix-Marseille UniversitéMarseilleFrance
  5. 5.Unité Hospitalière Sécurisée Interrégionale, Service de médecine en milieu pénitentiaireAssistance Publique – Hôpitaux de Marseille, Hôpital NordMarseilleFrance
  6. 6.Service Oncologie multidisciplinaire et innovations thérapeutiquesAssistance Publique – Hôpitaux de Marseille, Hôpital NordMarseilleFrance
  7. 7.Aix Marseille UniversitéMarseilleFrance
  8. 8.Service d’Information MédicaleAssistance Publique – Hôpitaux de Marseille, Hôpital NordMarseilleFrance
  9. 9.Service de Médecine légale et pénitentiaireHôpital Rangueil, Centre Hospitalier Universitaire de ToulouseToulouseFrance
  10. 10.UMR 5288, CNRS, Faculté de Médecine PurpanUniversité Toulouse IIIToulouseFrance
  11. 11.Service de pneumologieHôpital Larrey, Centre Hospitalier Universitaire de ToulouseToulouseFrance
  12. 12.Université Toulouse III - Paul SabatierToulouseFrance
  13. 13.Département d’Information MédicaleHôtel-Dieu Saint-Jacques, Centre Hospitalier Universitaire de ToulouseToulouseFrance
  14. 14.UMR 1027 INSERM - Université Toulouse III - Paul SabatierToulouseFrance
  15. 15.Service de Pneumologie Aigue Spécialisée et Cancérologie ThoraciqueCentre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de LyonPierre BéniteFrance
  16. 16.EMR3738 Ciblage thérapeutique en oncologie, Faculté de Médecine Lyon Sud-Charles MérieuxUniversité Lyon 1OullinsFrance

Personalised recommendations